NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: CleanGo Innovations' Subsidiary Kubera Black Technology to Acquire Freia Farmaceutici Srl
TL;DR
CleanGo Innovations acquires Freia Farmaceutici to gain a competitive edge in the global health sector with plant-based therapeutics and access to European markets.
CleanGo's subsidiary Kubera will acquire Freia through a share exchange of up to 25 million shares, subject to due diligence and regulatory approvals within 45 days.
This acquisition promotes sustainable, plant-based therapeutic solutions with no known side effects, advancing ethical healthcare and disease prevention globally.
Freia's ALFALIFE brand uses vegetable omegas to treat cardiovascular diseases and child neuropsychiatry, while their aesthetic line targets healthy skin solutions.
Found this article helpful?
Share it with your network and spread the knowledge!
CleanGo Innovations Inc.'s wholly-owned subsidiary Kubera Black Technology Inc. has entered into a non-binding Letter of Intent to acquire Freia Farmaceutici Srl, an Italian pharmaceutical company specializing in plant-based therapeutics.
This proposed transaction represents a strategic move to expand CleanGo's market presence into the global health sector, gaining access to Freia's expertise in plant-based therapeutics and immediate entry into European, Canadian, and US markets.
Freia Farmaceutici Srl is a Milan-based pharmaceutical company established in 2009 that specializes in developing ethical and sustainable plant-based therapeutic solutions, including medical devices, nutritional supplements, and food for special medical purposes.
Freia specializes in vegetable Omegas (particularly the ALFALIFE brand for anti-inflammatory applications), CE Marked Medical Devices for dermatological conditions (Dermolife line), and advanced aesthetic medicine solutions (PROMEDIAL brand).
Freia generated over €3.1 million in gross revenue in 2024 (100% from the Italian market) with a net positive balance sheet, is on pace to exceed 2024 revenue in 2025, and plans to expand into other European markets while gaining access to North American markets through this acquisition.
Freia's pipeline focuses on increasing solutions in current therapeutic areas and developing new products in gynecology, gastroenterology, and pneumology fields, including a product with applications for Multiple Sclerosis that has promising ongoing clinical trials.
Kubera Black Technology entered into the non-binding Letter of Intent on December 16, 2025, with the LOI dated December 9, 2025.
Freia's plant-derived therapeutic solutions utilize vegetable sources with no known side effects, aligning with growing consumer awareness regarding well-being and disease prevention through ethical and sustainable development.
Freia gains immediate access to Canadian and US markets through CleanGo's corporate structure, while CleanGo expands into European markets through Freia's established presence in Italy and planned European expansion.
Curated from NewMediaWire
